ES2056108T3 - Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica. - Google Patents

Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.

Info

Publication number
ES2056108T3
ES2056108T3 ES88305934T ES88305934T ES2056108T3 ES 2056108 T3 ES2056108 T3 ES 2056108T3 ES 88305934 T ES88305934 T ES 88305934T ES 88305934 T ES88305934 T ES 88305934T ES 2056108 T3 ES2056108 T3 ES 2056108T3
Authority
ES
Spain
Prior art keywords
antibody
biological activity
molecule
complex
inactivation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88305934T
Other languages
English (en)
Inventor
Ezekiel Y Shami
Aser Rothstein
Mohabir Ramjeesingh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybrisens Ltd
Original Assignee
Hybrisens Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybrisens Ltd filed Critical Hybrisens Ltd
Application granted granted Critical
Publication of ES2056108T3 publication Critical patent/ES2056108T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6815—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6871—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting an enzyme
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PUEDE PRODUCIR UN COMPLEJO QUE COMPRENDE (I) UNA MOLECULA QUE TIENE UNA ACTIVIDAD BIOLOGICA E (II) UN ENTE ANTICUERPO QUE RECONOCE LA MOLECULA, QUE MUESTRA LA ACTIVIDAD BIOLOGICA, QUE ES RESISTENTE A LA INACTIVACION EN RELACION CON LA DE LA MOLECULA. LA MOLECULA BIOLOGICAMENTE ACTIVA PUEDE SER UN ENZIMA, POR EJEMPLO, Y SE PUEDE UTILIZAR PARA PRODUCIR UN COMPLEJO CON UN ANTICUERPO O PROTEINA ENLAZANTE DE ANTIGENO, QUE RESISTE LA INACTIVACION QUE RESULTA DE UN PROCESO FISICO, QUIMICO O BIOLOGICO. ASI, EL COMPLEJO RESISTENTE A LA ACTIVACION MUESTRA ACTIVIDAD PROLONGADA BAJO CONDICIONES CARACTERIZADAS POR TEMPERATURA DE ROTURA, EN PRESENCIA DE UN ENZIMA PROTEOLITICO, PH DE ROTURA, LA PRESENCIA DE UN AGENTE OXIDANTE Y/O LA PRESENCIA DE UN ALCOHOL, ENTRE OTROS.
ES88305934T 1987-07-07 1988-06-30 Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica. Expired - Lifetime ES2056108T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7186187A 1987-07-07 1987-07-07
US18253088A 1988-04-18 1988-04-18
US20574888A 1988-06-21 1988-06-21

Publications (1)

Publication Number Publication Date
ES2056108T3 true ES2056108T3 (es) 1994-10-01

Family

ID=27371979

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88305934T Expired - Lifetime ES2056108T3 (es) 1987-07-07 1988-06-30 Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.

Country Status (7)

Country Link
EP (1) EP0298654B1 (es)
JP (1) JPH01138461A (es)
AT (1) ATE106250T1 (es)
AU (1) AU1865288A (es)
DE (1) DE3889783T2 (es)
DK (1) DK375188A (es)
ES (1) ES2056108T3 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686579A (en) * 1988-06-21 1997-11-11 Hybrisens, Ltd. Use of antibody/antigen interactions to protect biologically active proteins and peptides
JPH03133378A (ja) * 1989-07-19 1991-06-06 Modrovich Ivan E 被験体を安定化させて液体中でのその生物学的活性を保存する方法
ES2148144T3 (es) * 1990-11-20 2000-10-16 Dade Behring Marburg Gmbh Procedimiento para la estabilizacion de conjugados de enzima.
AU6849796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled enzymatic activity
AU6953796A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled cellulolytic activity
AU6777296A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled lipolytic activity
WO1998007819A1 (en) * 1996-08-16 1998-02-26 The Procter & Gamble Company Detergent compositions comprising antibody controlled proteolytic activity
AU6848896A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising oxido-reductase antibody
AU6953696A (en) * 1996-08-16 1998-03-06 Procter & Gamble Company, The Detergent compositions comprising antibody controlled amylolytic activity
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
CA2561732A1 (en) * 2004-03-30 2005-10-13 Takeda Pharmaceutical Company Limited Antibody drug
KR20070084069A (ko) * 2004-10-08 2007-08-24 도만티스 리미티드 Ｔｎｆｒ1에 대한 단일 도메인 항체 및 이의 사용 방법
JP2009525319A (ja) 2006-02-02 2009-07-09 ライナット ニューロサイエンス コーポレイション ｔｒｋＢアンタゴニストを投与することにより肥満を治療する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0231649B1 (en) * 1985-12-28 1990-11-22 Nippon Hypox Laboratories Incorporated Albumin complex
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US4704692A (en) * 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides

Also Published As

Publication number Publication date
DK375188D0 (da) 1988-07-06
JPH01138461A (ja) 1989-05-31
EP0298654B1 (en) 1994-06-01
DK375188A (da) 1989-01-08
EP0298654A2 (en) 1989-01-11
AU1865288A (en) 1989-01-12
DE3889783D1 (de) 1994-07-07
DE3889783T2 (de) 1994-09-08
ATE106250T1 (de) 1994-06-15
EP0298654A3 (en) 1990-02-07

Similar Documents

Publication Publication Date Title
ES2056108T3 (es) Empleo de interacciones anticuerpo/antigeno para proteger o modular la actividad biologica.
DE68903558D1 (de) Verfahren zur inaktivierung von viren.
NO903771L (no) Akrylsyrederivater.
DE3888642D1 (de) Rollflasche zur Züchtung von Zellengewebekulturen.
ATE42206T1 (de) Verfahren und zusammensetzung zur gleichzeitigen reinigung und desinfektion von kontaktlinsen.
ATE5898T1 (de) Verfahren zur enzymatischen glucoseoxidation.
DE69324745D1 (de) Flüssiges Thromboplastin-Reagens
DK349581A (da) C-076 makrolider og fremgangsmaade til fremstilling deraf
EP0188262A3 (en) Process for the isolation of chicken egg white cystatine, antiviral agents containing it and its use as viral protease inhibitor
FR2435526B1 (fr) Procede et appareil pour l'hydrolyse de sucre, proteines ou substances analogues
ATE129012T1 (de) Enzymatische oxidation von ceph c zu glutaryl-7- aminocephalosporansäure.
ES478533A1 (es) Un procedimiento para eliminar melamina de liquidos que con-tienen melamina.
ES2016227A4 (es) 54- procedimiento para la elaboracion de aminoacidos l-alfa.
NO180643C (no) Alkalisk pullulanase Y med <alfa>-amylaseaktivitet og en biologisk renkultur av Bacillus sp. mikroorganisme som produserer denne
ES2099678B1 (es) Procedimiento para la inactivacion de virus en proteinas.
DK142380A (da) Fremgangsmaade til fremstilling af pentadecapeptider
DK0457035T3 (da) Fremgangsmåde til inaktivering af den biologiske aktivitet af DNA
ATE139118T1 (de) Ribozymenhemmer
DK268589D0 (da) Fremgangsmaade til inaktivering af rekombinant dna
SE8600987D0 (sv) Forfarande for framstellning av ett protein- koncentrat ur helblod
ES2141258T3 (es) Enzima y su uso en la preparacion de acido (s)-pipecolico.
FR2355506A1 (fr) Adjuvant d'immunotherapie contenant un glycolipide comme ingredient actif et son procede de preparation
RU93008907A (ru) Способ получения иммобилизованных ферментов
DE3882654D1 (de) Enzymhemmer und methode zu dessen herstellung.
ITMI910861A1 (it) Procedimento migliorato per la preparazione di polipeptidi maturi

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 298654

Country of ref document: ES